Key result
Danhong injection plus MSCs improves post-MI cardiac function vs monotherapy in mice via enhanced MSC survival.
Why the study?
Poor implantation and survival of mesenchymal stem cells in ischemic myocardium restrict their efficacy in treating myocardial infarction.
Does Danhong injection combined with mesenchymal stem cells improve MSC survival and cardiac function in myocardial infarcted mice?
Does Danhong injection combined with mesenchymal stem cells improve MSC survival and cardiac function in myocardial infarcted mice?
Danhong injection enhances the therapeutic efficacy and survival of mesenchymal stem cells in a mouse model of myocardial infarction by modulating the SDF1/CXCR4 signaling pathway.
Answers are grounded in this paper and cite their sources.
May enhance MSC retention post-MI in preclinical models; leaves open clinical translation pending rigorous trials.
Stem cell-based therapies have the potential to dramatically transform the treatment and prognosis of myocardial infarction (MI), and mesenchymal stem cells (MSCs) have been suggested as a promising cell population to ameliorate the heart remodeling in post-MI. However, poor implantation and survival in ischemic myocardium restrict its efficacy and application. In this study, we sought to use the unique mode of action of Chinese medicine to improve this situation. Surrounding the myocardial infarct area, we performed a multi-point MSC transplantation and administered in conjunction with Danhong injection, which is mainly used for the treatment of MI. Our results showed that the MSC survival rate and cardiac function were improved significantly through the small animal imaging system and echocardiography, respectively. Moreover, histological analysis showed that MSC combined with DHI intervention significantly reduced myocardial infarct size in myocardial infarcted mice and significantly increased MSC resident. To investigate the mechanism of DHI promoting MSC survival and cell migration, PCR and WB experiments were performed. Our results showed that DHI could promote the expression of CXC chemokine receptor 4 in MSC and enhance the expression of stromal cell-derived factor-1 in myocardium, and this effect can be inhibited by AMD3100 (an SDF1/CXCR4 antagonist). Additionally, MSC in combination with DHI interfered with MI in mice and this signifies that when combined, the duo could the expression of vascular endothelial growth factor (VEGF) in the marginal zone of infarction compared with when either MSC or DHI are used individually. Based on these results, we conclude that DHI enhances the residence of MSCs in cardiac tissue by modulating the SDF1/CXCR4 signaling pathway. These findings have important therapeutic implications for Chinese medicine-assisted cell-based therapy strategies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) studied Myocardial infarction (n=40). Danhong injection combined with Mesenchymal Stem Cells vs. Saline (model group), MSCs alone, or DHI alone was evaluated on Cardiac function (LVEF, FS) and MSC retention rate (p=<0.05). Danhong injection combined with mesenchymal stem cell transplantation significantly improved cardiac function, reduced infarct size, and enhanced MSC survival in a mouse model of myocardial infarction compared to either treatment alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: